Deva Holding AS

Deva Holding AS has a liquidity position that is medium in risk, with a current ratio of 1.65, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt metric shows a net cash position that is negative after subtracting total debt, which suggests that the company's cash and equivalents are insufficient to cover its long-term debt obligations. The company's profitability is weak, with a return on equity of -3.07% and a return on assets of -2.14%, both of which are below the typical thresholds for healthy performance in the pharmaceutical industry. The operating income of 758.15 million TRY is significantly lower than the gross profit of 6.3 billion TRY, indicating high operating expenses or inefficiencies in the company's operations. Deva Holding AS's revenue is concentrated in Turkey, as all four of its production facilities are located in the country, and it does not disclose significant international revenue in the provided data. The company's product portfolio includes 73 drugs, but the geographic exposure is not detailed beyond the domestic market. The company's growth trajectory is uncertain, with a net income of -806.99 million TRY in the latest period, indicating a loss. The outlook for the current fiscal year does not provide specific numeric deltas, but the negative net income suggests a challenging growth environment. The company's capital expenditure of -2.36 billion TRY indicates significant investment in its operations, which could be a sign of expansion or modernization. The risk assessment for Deva Holding AS includes a medium liquidity risk and a low dilution risk. The company's debt to equity ratio of 0.23 suggests a relatively conservative capital structure, but the negative net cash position after subtracting total debt is a concern. The company has not disclosed any recent dilution events, and the dilution potential is considered low. Recent events for Deva Holding AS include the latest financial snapshot, which shows a net loss and significant capital expenditure. The company's free cash flow is negative at -1.55 billion TRY, indicating that the company is not generating enough cash from operations to cover its capital expenditures. The company's operating cash flow of 4.99 billion TRY is positive, but it is not sufficient to offset the capital expenditures and maintain a positive free cash flow.